Hot Investor Mandate: Corporate VC Arm of Asian Pharmaceutical Group Invests Up to $20M in Therapeutics Companies, Helps Overseas Companies with Expansion Into Asia

16 Sep

The corporate venture of a publicly listed pharmaceutical group in Asia has successfully invested and established 7 IPO companies in Taiwan and Hong Kong. The firm now focuses on strategic investments which can synergize with its portfolio companies or future business. The firm is open to consider investment opportunities globally, and is willing to help overseas portfolio companies enter into Asia through licensing or joint venture activities. Typical allocation size can range from US$3-20 million.

The firm is investing strategically in selected sectors. Within therapeutics, the firm considers in companies with technology platforms in cell therapy, RNA therapies, bispecific and ADC drugs.  Investment stage can range from preclinical to early clinical stage.  The firm is also interested in investing in early stage CDMO companies in the areas above.

The firm is looking for experienced management teams with proven track records. The firm typically requests a board seat in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: